Importance Approximately 125 million people worldwide have psoriasis. Patients with
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …

Objective: To develop an evidence-based guideline for the pharmacologic and
nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the …

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Genetic
predisposition, epidermal barrier disruption, and dysregulation of the immune system are …

Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …

Innate immunity represents the semi-specific first line of defense and provides the initial host
response to tissue injury, trauma, and pathogens. Innate immunity activates the adaptive …

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Psoriasis vulgaris is a common, heterogeneous, chronic inflammatory skin disease
characterized by thickened, red, scaly plaques and systemic inflammation. Psoriasis is also …

Background Wide-ranging prevalence estimates of psoriatic arthritis (PsA) in patients with
psoriasis have been reported. Objectives To assess the prevalence and incidence of PsA in …

Background Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We
evaluated secukinumab, a fully human anti–interleukin-17A monoclonal antibody, in …